Stay updated with breaking news from Preclinical Models. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...